Related Experiment Video
Updated: Jan 11, 2026
Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia
Published on: June 28, 2018
Human Metapneumovirus Hospitalisation in Children: A Retrospective Audit
R A Hibbert1,2, D R Cheng1,2, Alissa McMinn2
1Department of General Medicine, The Royal Children's Hospital, Parkville, Australia.
Insights
Human Metapneumovirus (hMPV) hospitalizations are common in young children. Children under two and those with comorbidities face higher risks of severe illness and ICU admission, highlighting the need for prevention strategies.
Area of Science:
- Pediatric Infectious Diseases
- Virology
- Public Health
Background:
- Human Metapneumovirus (hMPV) is a significant cause of pediatric hospitalizations.
- Currently, no licensed vaccines or specific antiviral treatments exist for hMPV.
- Understanding hMPV's clinical impact and risk factors is crucial for developing interventions.
Purpose of the Study:
- To characterize the clinical profile and seasonality of hMPV hospitalizations in children.
- To identify children at higher risk for severe hMPV disease.
- To inform the development of preventative strategies.
Main Methods:
- Retrospective audit of pediatric patients (0-18 years) with positive hMPV PCR tests.
- Data collected from May 2016 to December 2023 at a quaternary children's hospital.
- Analysis included clinical and epidemiological data.
Main Results:
- 1296 children were included; 50% were under 2 years old.
- Seasonality showed a typical winter rise, interrupted by COVID-19, with a subsequent rebound.
- Children with comorbidities (41.2%) had longer hospital stays and higher ICU admission rates (16.1% vs. 6.7%).
- Three deaths occurred within 30 days, all in children with underlying malignancies.
Conclusions:
- hMPV significantly impacts pediatric hospitalizations, especially in infants and those with comorbidities.
- Younger children (<2 years) and those with comorbidities are at increased risk for severe outcomes, including ICU admission.
- There is an urgent need for effective prevention strategies against hMPV infection in children.
Aim:
Human Metapneumovirus (hMPV) is a common cause of hospitalisation in children; yet there are currently no preventative licensed vaccines or specific treatments available. Our aim was to describe the clinical profile and seasonality of hospitalised children with hMPV, and to highlight those at higher risk of severe disease.
Methods:
We conducted a retrospective audit at a single quaternary centre, The Royal Children's Hospital Melbourne, Australia. Clinical and epidemiological data were extracted from the electronic medical record for any child (0-18 years) with a positive respiratory Polymerase Chain Reaction (PCR) test for hMPV between May 2016 and December 2023 (study duration 7.5 years).
Results:
A total of 1296 children who tested positive for hMPV between May 2016 and December 2023 were included in our study. Children aged < 2 years made up 50% of the cohort (n = 648). Seasonality reflected a consistent end-of-winter rise in case numbers, except during the COVID-19 pandemic when there were no reported cases of hMPV but a spike in case numbers the following year. Of those admitted, 41.2% had a comorbidity such as prematurity, cerebral palsy or malignancy. Children with comorbidities were more likely to have a longer duration of hospital stay with a median of 3 days (IQR 1-7) compared with 1 day (IQR 0-3) and be admitted to the Intensive Care Unit (ICU) (16.1% compared with 6.7%). Three children died within 30 days of returning a positive PCR, all of whom had an underlying malignancy.
Conclusions:
Our study describes the impact of hMPV on hospitalisation at a quaternary centre. Younger children, particularly those aged < 2 years, and those with comorbidities were at a higher risk of ICU admission. Prevention strategies are needed to protect children from hMPV infection.
Related Concept Videos
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia III: Complications and Assessment
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:29Pneumonia II: Pathophysiology
01:21Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include: